Pharmacokinetics and drug interactions of antidepressive agents

Y. Sawada, Hisakazu Ohtani

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Tricyclic antidepressive agents(TCAs) are conventional antidepressant. Cytochrome P450(CYP) 2D6 is involved in the hydroxylation of TCAs, while N-demethylation of TCAs is mediated by other such as CYP2C19, 3A4 and 1A2. The elimination of TCAs is impaired by CYP2D6 inhibitors such as quinidine. Newer antidepressants, selective serotonin uptake inhibitors(SSRIs), are also metabolized in the liver. Fluvoxamine, an SSRI, is a potent inhibitors for CYP1A2 and CYP2C19, moderate for CYP3A4 and weak for CYP 2D6. Paroxetine, another SSRI, causes substantial inhibition of CYP2D6 activity. Milnacipran, a serotonin and noradrenaline reuptake inhibitor, is mainly excreted unchanged in urine and some part as its glucronide conjugate. In contrast to many SSRIs, milnacipran is devoid of metabolic inhibition.

Original languageEnglish
Pages (from-to)1539-1545
Number of pages7
JournalNippon rinsho. Japanese journal of clinical medicine
Volume59
Issue number8
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Tricyclic Antidepressive Agents
Serotonin Uptake Inhibitors
Drug Interactions
Cytochrome P-450 CYP2D6
Antidepressive Agents
Pharmacokinetics
Fluvoxamine
Cytochrome P-450 CYP3A
Paroxetine
Quinidine
Hydroxylation
Urine
Liver
milnacipran

Cite this

Pharmacokinetics and drug interactions of antidepressive agents. / Sawada, Y.; Ohtani, Hisakazu.

In: Nippon rinsho. Japanese journal of clinical medicine, Vol. 59, No. 8, 2001, p. 1539-1545.

Research output: Contribution to journalArticle

@article{2d4b8a08935147deb7eb7e65db435b41,
title = "Pharmacokinetics and drug interactions of antidepressive agents",
abstract = "Tricyclic antidepressive agents(TCAs) are conventional antidepressant. Cytochrome P450(CYP) 2D6 is involved in the hydroxylation of TCAs, while N-demethylation of TCAs is mediated by other such as CYP2C19, 3A4 and 1A2. The elimination of TCAs is impaired by CYP2D6 inhibitors such as quinidine. Newer antidepressants, selective serotonin uptake inhibitors(SSRIs), are also metabolized in the liver. Fluvoxamine, an SSRI, is a potent inhibitors for CYP1A2 and CYP2C19, moderate for CYP3A4 and weak for CYP 2D6. Paroxetine, another SSRI, causes substantial inhibition of CYP2D6 activity. Milnacipran, a serotonin and noradrenaline reuptake inhibitor, is mainly excreted unchanged in urine and some part as its glucronide conjugate. In contrast to many SSRIs, milnacipran is devoid of metabolic inhibition.",
author = "Y. Sawada and Hisakazu Ohtani",
year = "2001",
language = "English",
volume = "59",
pages = "1539--1545",
journal = "Nihon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "8",

}

TY - JOUR

T1 - Pharmacokinetics and drug interactions of antidepressive agents

AU - Sawada, Y.

AU - Ohtani, Hisakazu

PY - 2001

Y1 - 2001

N2 - Tricyclic antidepressive agents(TCAs) are conventional antidepressant. Cytochrome P450(CYP) 2D6 is involved in the hydroxylation of TCAs, while N-demethylation of TCAs is mediated by other such as CYP2C19, 3A4 and 1A2. The elimination of TCAs is impaired by CYP2D6 inhibitors such as quinidine. Newer antidepressants, selective serotonin uptake inhibitors(SSRIs), are also metabolized in the liver. Fluvoxamine, an SSRI, is a potent inhibitors for CYP1A2 and CYP2C19, moderate for CYP3A4 and weak for CYP 2D6. Paroxetine, another SSRI, causes substantial inhibition of CYP2D6 activity. Milnacipran, a serotonin and noradrenaline reuptake inhibitor, is mainly excreted unchanged in urine and some part as its glucronide conjugate. In contrast to many SSRIs, milnacipran is devoid of metabolic inhibition.

AB - Tricyclic antidepressive agents(TCAs) are conventional antidepressant. Cytochrome P450(CYP) 2D6 is involved in the hydroxylation of TCAs, while N-demethylation of TCAs is mediated by other such as CYP2C19, 3A4 and 1A2. The elimination of TCAs is impaired by CYP2D6 inhibitors such as quinidine. Newer antidepressants, selective serotonin uptake inhibitors(SSRIs), are also metabolized in the liver. Fluvoxamine, an SSRI, is a potent inhibitors for CYP1A2 and CYP2C19, moderate for CYP3A4 and weak for CYP 2D6. Paroxetine, another SSRI, causes substantial inhibition of CYP2D6 activity. Milnacipran, a serotonin and noradrenaline reuptake inhibitor, is mainly excreted unchanged in urine and some part as its glucronide conjugate. In contrast to many SSRIs, milnacipran is devoid of metabolic inhibition.

UR - http://www.scopus.com/inward/record.url?scp=0035430588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035430588&partnerID=8YFLogxK

M3 - Article

C2 - 11519155

AN - SCOPUS:0035430588

VL - 59

SP - 1539

EP - 1545

JO - Nihon rinsho. Japanese journal of clinical medicine

JF - Nihon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 8

ER -